▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China
Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List
The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China
This Q&A explores the growing gap between global pharma strategies and China’s payer priorities—offering a self-assessment tool for internal alignment, and insights into risks and opportunities in the commercial catalog pathway.
Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines
Gain practical tools and insight to navigate China’s C-List and Commercial Catalog—and make informed decisions on product positioning across emerging access pathways.
China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback
As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List
Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines
The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
